Most Read Articles
Roshini Claire Anthony, 5 days ago

Individuals with moderate-to-severe plaque psoriasis may reap better long-term improvements in the severity of their condition when treated with guselkumab over secukinumab, according to findings of the phase III ECLIPSE* trial presented at the recent Inflammatory Skin Disease Summit (ISDS 2018) held in Vienna, Austria.

Jairia Dela Cruz, 11 Jan 2019
Use of standard-dose aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs) appears to confer protection against the risk of endometrial cancer in overweight and obese women, according to a meta-analysis.
Elvira Manzano, 6 days ago
Treatment with two investigational, oral JAK inhibitors may be beneficial in individuals with moderate‐to‐severe alopecia areata (spot baldness), an autoimmune disease that can cause a lot of anxiety, according to an ongoing phase II study.
4 days ago
Discontinuing the use of tyrosine kinase inhibitors (TKIs) in the treatment of patients with chronic myeloid leukaemia appears to be feasible in real-life clinical practice in the context of close molecular monitoring, a study reports.

Beauty care improves mental health, quality of life in breast cancer patients

06 Jan 2019
Most of the products involved were not categorised as cosmetics, but were actually pharmaceutical products, which are not registered under the Drug Control Authority.

Beauty care appears to yield short-term and midterm improvements in psychosocial outcomes in patients with early breast cancer, a recent study has found.

The study included 39 female primary breast cancer patients who were randomly assigned to an immediate intervention (n=20; mean age 39.6±9.35 years) or waitlist control (n=19; mean age 37.4±9.60 years) group. The intervention involved a group makeup workshop, a photo session and the receipt of professionally edited photographs.

The intervention had immediate benefits on depressive symptoms. Mean scores dropped from 20.0±5.03 at the start of the session to 15.1±3.33 by the end (p<0.001).

Researchers also observed a short-term benefit of the beauty care intervention. Depressive symptoms were significantly reduced by the first follow-up, which occurred after the immediate intervention but not in the waitlist group had undergone the workshop (MD, –11.9; p=0.001).

This effect persisted until the second follow-up, which took place after the immediate intervention but not in the waitlist group who had received their photos (MD, –8.10; p=0.006). Baseline depressive symptom scores were statistically comparable between the groups (MD, –4.12; p=0.229).

Notably, scores did not differ between the second and third follow-up sessions for both groups, indicating that scores had stabilized by this point.

Similar trends were observed for quality of life, which was significantly higher in the immediate intervention group at both the first (MD, 16.8; p=0.010) and second (MD, 16.7; p=0.009) follow-ups. Baseline values were comparable between groups (MD, 7.85; p=0.271).

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Oncology - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Roshini Claire Anthony, 5 days ago

Individuals with moderate-to-severe plaque psoriasis may reap better long-term improvements in the severity of their condition when treated with guselkumab over secukinumab, according to findings of the phase III ECLIPSE* trial presented at the recent Inflammatory Skin Disease Summit (ISDS 2018) held in Vienna, Austria.

Jairia Dela Cruz, 11 Jan 2019
Use of standard-dose aspirin or other nonsteroidal anti-inflammatory drugs (NSAIDs) appears to confer protection against the risk of endometrial cancer in overweight and obese women, according to a meta-analysis.
Elvira Manzano, 6 days ago
Treatment with two investigational, oral JAK inhibitors may be beneficial in individuals with moderate‐to‐severe alopecia areata (spot baldness), an autoimmune disease that can cause a lot of anxiety, according to an ongoing phase II study.
4 days ago
Discontinuing the use of tyrosine kinase inhibitors (TKIs) in the treatment of patients with chronic myeloid leukaemia appears to be feasible in real-life clinical practice in the context of close molecular monitoring, a study reports.